TIGIT blockade is being evaluated in multiple clinical trials, including phase III studies for advanced non-small cell lung cancer (NSCLC) and melanoma, and phase II basket trials for solid tumors, although none treating RCC specifically (NCT04294810, NCT05665595, NCT04693234, NCT03708224). Here, TIGIT is linked to melanoma.